← ANALYST RATINGS · TIPRANKS
Innoviva (INVA): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $39.25, the highest $46.00, the lowest $34.00. The average is +88.9% from the last price of $20.78.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% | Truist Financial | $35.00 | Buy | +68.4% | Initiated | 23.09.26on TipRanks Sep 30 02:55 | −2.8%next day +2.2% · 5 days +5.5% | ↗ |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $34.00 | Buy | +63.6% | Reiterated | 20.08.26on TipRanks Aug 21 08:25 | −1.4%next day −0.1% · 5 days −1.3% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $46.00 | Buy | +121.4% | Reiterated | 10.08.26on TipRanks 06:27 | +0.9%next day +0.7% · 5 days +1.4% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $25.00 → $23.00−8.0% | Buy | +10.7% | Reiterated | 06.08.26on TipRanks 10:07 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $25.00 → $23.50−6.0% | Buy | +13.1% | Reiterated | 06.08.26on TipRanks 10:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.00 → $21.50−6.5% | Hold | +3.5% | Reiterated | 06.08.26on TipRanks 10:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $25.00 → $23.00−8.0% | Buy | +10.7% | Reiterated | 06.08.26on TipRanks 10:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $24.50 → $23.00−6.1% | Buy | +10.7% | Reiterated | 06.08.26on TipRanks 10:07 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $24.50 → $23.00−6.1% | Buy | +10.7% | Reiterated | 06.08.26on TipRanks 10:07 | — | |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $42.00 | Buy | +102.1% | Reiterated | 05.08.26on TipRanks Aug 6 06:05 | −1.5%next day +3.1% · 5 days +1.1% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $18.00 | Sell | −13.4% | Reiterated | 06.05.26on TipRanks May 7 07:15 | −2.0%next day +1.6% · 5 days +1.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Innoviva
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $39.25 at a price of $21.21 (+85.1%); now: $39.25 at $20.78 (+88.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 5 | 5 | 7 | 5 | 5 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.52 (from $0.47 to $0.57). Last quarter: $-1.14.
Sales
Next quarter’s sales estimate — $115M (from $104M to $133M). Last quarter: $123M.
Best top-analyst consensus in the sector · Healthcare
About Innoviva
- CEO: Pavel Raifeld
- Employees: 159
- 1350 Old Bayshore Highway, Burlingame, CA, 94010, US
- www.inva.com
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Data from the stock’s TipRanks forecast page, read 210 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗